Heart failure & cardiomyopathiesCohort study
Sex Differences in the Prognostic Role of Achieving Target Doses of Heart Failure Medications: Data from the Swedish Heart Failure Registry
- Registry-based cohort study
- Swedish heart failure (HF) Registry
- multivariable Cox regression
Authors' conclusion
Our findings suggest that females and males might differently benefit from the same dose of RASI/ARNI
Study context
- Population
- Patients with HFrEF and HF duration ≥6 months registered in the Swedish HF Registry, May 2000–December 202029% female
- Participants
- 17,912 patients
- Exposure
- Females vs Males
- Outcome
- CV mortality or hospitalization for HF across dose categories, females vs males
- Follow-up
- Median 1.33 years (IQR 0.29-3.22)
Main finding
As reported in the abstract
CV mortality or HF hospitalization, by sex and achieved % of target dose · median follow-up 1.33 years
Hazard ratio
0.92
95% CI 0.83–1.03
Females achieving 50-99% of TD (RASI/ARNI) vs Females achieving 100% of TD (RASI/ARNI)
HR 0.92 (95% CI 0.83–1.03)
- Sex interaction for renin-angiotensin system inhibitors (RASI)/angiotensin receptor-neprilysin inhibitors (ARNI)
- P for interaction = 0.030
Observational data: associations, not effects.
Original publication
Sex Differences in the Prognostic Role of Achieving Target Doses of Heart Failure Medications: Data from the Swedish Heart Failure Registry. Eur J Heart Fail. Published 2 May 2024. doi:10.1002/ejhf.3272
Summarised from the published abstract; every number is checked against it